World's First and Only Genetically Attuned Health and Medical Capabilities
Forging A New Era Of Health & Medical Capabilities

R & D Applications
Our overall discoveries can also be incorporated into the main research and development processes involved with just about any other type of medical science so as to greatly refine and enhance these processes for much faster, more reliable and more highly defined results.

The following are some more examples of how the underpinnings of our medical technologies can be utilised to produce more effective, efficient and safer treatment outcomes.


Therapeutics Research & Development


Due to our overall discoveries and developments, not only can currently existing treatments be substantially improved upon but hundreds, if not thousands, of new therapeutic products can be developed that target the same and/or similar systems as current treatments but simply via new pathways, receptors and so on.

This also includes the development of a number of companion and synergistic treatment methods, utilising both new and existing substances, that can work systematically to substantially enhance treatment outcomes.

Furthermore, all of this also means that:
  1. in many instances far lower dosages of substances can be utilised yet with the same or better therapeutic outcomes;
  2. where the diagnosed need is ascertained, dosage rates can usually be increased substantially past currently prescribed dosage rates without toxicity occurring;
  3. new candidate substances and formulas can be assessed for usefulness and viability far more quickly and effectively;
  4. many substances that have previously not made it through to commercialisation and/or have not shown any reasonable usefulness can readily be re-assessed to see if the whole problem with them was simply that they were actually being assimilated into conflicting pathways, receptor systems and so on;
  5. many substances can be reformulated to make them better and/or usable for both known and novel indications;
  6. many combination products can be developed for both known and novel indications;
  7. many new genetic, biochemical and general biological systems can now be defined and utilised to produce numerous new and/or advanced therapeutics as well as many new and/or advanced research and diagnostic tools; and
  8. many genetic, biochemical and general biological systems (and their related medical conditions) that are currently very difficult to target, either for research or treatment purposes, can either now or in the near future be readily targeted.
Initial testing of our new know how on a number of already existing and approved substances (over 200 so far) has shown nothing short of remarkable findings – including that of just how precise, effective and extensive the overall underpinnings of our medical technologies really are.

We have also conducted some minimal initial trials of some of these substances in relation to conditions such as: rhinitis; asthma; insomnia; muscular joint problems; hives reactions; mental diseases and general mood disorders; sinus and chest congestion; back problems; drug addictions; general immuno support; libido and fertility issues; inflammatory conditions; viral and bacterial infections; and analgesia – all with profound effectiveness and safety!

It should also be pointed out that we have also successfully determined that our new technologies can also be utilised for use with both topical and injectible applications in exactly the same manner.


Novel & Advanced Platform Applications


It is important to note that the overall underpinnings of our medical technologies will foster an explosion of new and highly focused research and development that will, in turn, also foster an explosion of both new and more highly evolved knowledge in most all fields of medical science and biotechnology in general.

In fact, with ongoing research and development it is highly envisaged that numerous extensive breakthroughs and general developments will eventuate relative to many industry sectors, including application areas that are currently under-established and/or underutilised.

Having said all of this, it is important to note that the underpinnings of our medical technologies can be utilised to further produce various patent protectable commercial outcomes relative to:
  • Novel and more highly advanced models of disease which far more accurately predict human molecular processes and disease pathologies
  • Novel and more highly advanced, defined and accurate early predictors of human ADME/tox
  • Novel and more highly advanced, defined and accurate in vitro tissue-mimicking toxicology assays
  • Novel and more highly advanced, defined and accurate computational models of in vitro and clinical trial response
  • Novel and more highly advanced methods of improving substance stability, cell permeability and tissue targeting (including that relative to nanotechnologies)
  • Novel and more highly advanced methods of systems biology/multi-marker patterns and protein/antibody arrays
  • Novel and more highly advanced antibody discovery and antibody enhancement platforms and with the ability to determine antibody alternatives with superior properties
  • Novel and more highly advanced protein and gene expression manipulation and amplification (programming) platforms – for both advanced and novel medical treatment methods as well as for general biological enhancement purposes
  • Novel and more highly advanced substance and treatment discovery platforms with the ability to determine a vast array of new candidates and/or new applications
  • Novel discovery platforms for highly effective nutraceutical, phytoceutical and zooceutical based therapies
  • Novel platforms for combination therapies
  • Novel and more highly advanced diagnostic procedures, models, test kits, metabolic profiling and metabolic paneling – including in relation to genetic testing
Most importantly, all of this also includes major breakthroughs in understanding why in vitro studies and animal models do not translate well into human evaluations and trials as well as how to resolve many of these underlying issues.


Cutting Costs & Lead Times


It is also very important to note that both the time frames and the costs associated with fully developing all technologies and treatments to commercial rollout (as well as that of many of the other new technologies that will evolve) should be substantially reduced due to our new knowledge of how to both inhibit/minimise side effects as well as how to actually develop the products and services based on specific programmed and programmable metabolic expression attributes.

Our breakthrough findings and developments will inevitably lead to much faster and easier regulatory fulfilments and this will inevitably also lead to much cheaper research and development cost, thus resulting in much cheaper products and services for both the industry and consumers alike.


For information regarding the development pipeline of this technology, please click here.
Bookmark and Share
..........................................
Members Area
Username:

Password:
Retrieve Password
Enter your Email Address or
Username:
Menu
Introduction
Our Newly Discovered Metabolic Networks
Our Metabolic Amplification Platform Technology
Nutraceutical Applications
Pharmaceutical Applications
Phytoceutical Applications
Zooceutical Applications
R & D Applications
Diagnostic Applications
Our Medical Treatments
Advanced Hydrocolloids
Partnering With Us
Technology Pipeline
 
 
Home | Disclaimer | User Agreement | Privacy Policy | Contact Us
Copyright 2010-2011 BC Biogenics Pty Ltd. All rights reserved.